In vivo data clearly demonstrated that the TGFβ-trap architecture enhanced anti-tumor capability of EGFRvIII-specific CAR-Ts in a TGFβ context and prolonged survival of GBM-bearing mice. The gene discussed is TGFB1; the disease is neoplasm.